Literature DB >> 30599062

Associations between plasma nesfatin-1 levels and the presence and severity of coronary artery disease.

Susumu Ibe1, Yoshimi Kishimoto2, Hanako Niki1, Emi Saita2, Tomohiko Umei1, Kotaro Miura1, Yukinori Ikegami1, Reiko Ohmori3, Kazuo Kondo2,4, Yukihiko Momiyama5.   

Abstract

Nesfatin-1 is a recently identified anorexigenic peptide mainly secreted from the brain and adipose tissue. Although nesfatin-1 may have pro-inflammatory and apoptotic properties, the association between plasma nesfatin-1 levels and coronary artery disease (CAD) has not been clarified yet. We investigated plasma nesfatin-1 levels in 302 patients undergoing elective coronary angiography. Of the 302 study patients, CAD was present in 172 (57%), of whom 67 had 1-vessel, 49 had 2-vessel, and 56 had 3-vessel disease. Compared with 130 patients without CAD, 172 with CAD had higher plasma nesfatin-1 levels (median 0.21 vs. 0.17 ng/mL, P < 0.01). A stepwise increase in nesfatin-1 levels was found depending on the number of > 50% stenotic coronary vessels: 0.17 in CAD(-), 0.20 in 1-vessel, 0.21 in 2-vessel, and 0.22 ng/mL in 3-vessel disease (P < 0.05). A high nesfatin-1 level (> 0.19 ng/mL) was found in 43% of patients with CAD(-), 55% of those with 1-vessel, 55% of those with 2-vessel, and 68% of those with 3-vessel disease (P < 0.05). Nesfatin-1 levels significantly correlated with the number of > 50% stenotic coronary segments (r = 0.14, P < 0.02). In multivariate analysis, plasma nesfatin-1 levels were a significant factor for CAD independent of atherosclerotic risk factors. The odds ratio for CAD was 1.71 (95% CI 1.01-2.91) for high nesfatin-1 level of > 0.19 ng/mL (P < 0.05). Thus, plasma nesfatin-1 levels were found to be high in patients with CAD and were associated with CAD independent of atherosclerotic risk factors, suggesting that high nesfatin-1 levels in patients with CAD may play a role in the development of coronary atherosclerosis.

Entities:  

Keywords:  Atherosclerosis; Biomarker; Coronary artery disease; Nesfatin-1

Mesh:

Substances:

Year:  2019        PMID: 30599062     DOI: 10.1007/s00380-018-01328-3

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  7 in total

1.  Nesfatin-1 Levels Predict Angiographic No-Reflow in Patients with ST-Segment Elevation Myocardial Infarction.

Authors:  Serkan Sivri; Erdoğan Sökmen; Mustafa Çelik; Kenan Güçlü
Journal:  Acta Cardiol Sin       Date:  2020-07       Impact factor: 2.672

Review 2.  "Sibling" battle or harmony: crosstalk between nesfatin-1 and ghrelin.

Authors:  Xi Chen; Jing Dong; Qian Jiao; Xixun Du; Mingxia Bi; Hong Jiang
Journal:  Cell Mol Life Sci       Date:  2022-03-03       Impact factor: 9.261

3.  High Plasma Levels of Soluble Talin-1 in Patients with Coronary Artery Disease.

Authors:  Masayuki Aoyama; Yoshimi Kishimoto; Emi Saita; Yukinori Ikegami; Reiko Ohmori; Masato Nakamura; Kazuo Kondo; Yukihiko Momiyama
Journal:  Dis Markers       Date:  2020-05-29       Impact factor: 3.434

4.  Association of circulating BMP9 with coronary heart disease and hypertension in Chinese populations.

Authors:  Rui Liu; Wenjing Hu; Xiaoqiang Li; Danlan Pu; Gangyi Yang; Hua Liu; Minghong Tan; Danping Zhu
Journal:  BMC Cardiovasc Disord       Date:  2019-05-30       Impact factor: 2.298

5.  Association between Plasma Sestrin2 Levels and the Presence and Severity of Coronary Artery Disease.

Authors:  Yoshimi Kishimoto; Masayuki Aoyama; Emi Saita; Yukinori Ikegami; Reiko Ohmori; Kazuo Kondo; Yukihiko Momiyama
Journal:  Dis Markers       Date:  2020-06-30       Impact factor: 3.434

Review 6.  Adipokines and Inflammation: Focus on Cardiovascular Diseases.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Sandra Moraña-Fernández; Laura Anido-Varela; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Isabel Moscoso; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  Int J Mol Sci       Date:  2020-10-18       Impact factor: 5.923

7.  Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study.

Authors:  Nikolaos P E Kadoglou; Emmanouil Korakas; Stylianos Lampropoulos; Eirini Maratou; George Kassimis; Nikolaos Patsourakos; Panagiotis Plotas; Paraskevi Moutsatsou; Vaia Lambadiari
Journal:  Cardiovasc Diabetol       Date:  2021-08-13       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.